The case for urgency is stark. In 2023 alone, commercialisation of atrazine in Brazil reached roughly 22,000 tons, with Alagoas and Mato Grosso leading consumption. The herbicide binds the D1 protein at the plastoquinone binding site of photosystem II, blocking electron transport and starving plants of the ATP and NADPH they need to survive. That same potency makes residues dangerous: the European Union banned atrazine in 2004 over carcinogenic concerns and its tendency to accumulate in soil and water. The International Agency for Research on Cancer classifies the compound as probably carcinogenic to humans, and a recent survey detected atrazine in over 40 percent of 8,146 groundwater monitoring wells across ten Chinese grain-producing regions, with most detections at depths approaching 52 metres.

The first leg of the proposed tripartite system is biochar, a charcoal-like material produced by pyrolysing agricultural and forestry waste such as corn stalks, peanut shells, coffee husks and eucalyptus chips under low-oxygen conditions. Its value as a remediation tool comes from structure and chemistry: enormous surface area, hierarchical porosity, and a wealth of oxygenated functional groups including hydroxyls, carboxyls and quinones. These features allow biochar to capture atrazine through hydrophobic interactions, hydrogen bonds and pi-pi stacking between the herbicide’s aromatic rings and the biochar’s condensed aromatic matrix. Biochar produced at high pyrolysis temperatures, which yields greater aromaticity, retains the most atrazine, and laboratory work shows that activating biochar with acids, bases or metal salts further intensifies its capture of herbicide molecules even at low concentrations.

Critically, the authors emphasise that biochar does not simply lock the herbicide away. Adsorption modulates bioavailability, holding atrazine in surface microzones where microbes can gradually reach it, while reducing mobility and leaching risk. In this sense biochar acts simultaneously as a chemical immobiliser and an indirect degradation promoter, creating sheltered microhabitats where bacterial colonisers can persist under chemical stress. It also improves the soil itself, neutralising acidity with calcium and magnesium carbonates, supplying potassium, phosphorus and micronutrients such as manganese, iron, copper, zinc and molybdenum, and boosting water retention and cation exchange capacity. Each ton of applied biochar can additionally sequester between 2.2 and 3.0 tons of carbon dioxide equivalent, tying remediation directly to climate benefits.

The second component, microbial bioremediation, exploits the metabolic versatility of Pseudomonas species. These bacteria carry enzymatic pathways that dismantle atrazine step by step: they first strip off the chlorinated group to yield hydroxyatrazine, then remove the ethylamine and isopropylamine side chains to produce cyanuric acid, and finally convert that intermediate into ammonium and carbon dioxide, achieving complete mineralisation of the parent compound. Because the microbes can multiply and maintain their degrading activity in the soil, costs fall over time, and studies suggest microbial bioremediation is economically superior to conventional physicochemical decontamination. Notably, seven years of sequential atrazine applications have been shown to naturally select for atrazine-degrading microorganisms, accelerating dissipation and preventing progressive environmental accumulation.

The third element, phytoremediation, brings plants into the picture as active partners rather than passive bystanders. Plants deploy a repertoire of mechanisms including phytoextraction, in which roots take up contaminants and translocate them to shoots; phytostabilisation, which immobilises pollutants in the root zone; phytodegradation, where internal enzymes break organic pollutants into simpler, less toxic molecules; rhizodegradation, driven by root exudates that fuel contaminant-eating microbes; and phytovolatilisation, which converts xenobiotics into volatile, less harmful forms. Some species even use atrazine as a nitrogen source, transforming it into less toxic metabolites or mineralising it entirely. Cost estimates reinforce the appeal: phytoremediation of heavy metals across 700 hectares was calculated at roughly 37.7 dollars per cubic metre, far below the 71.4 and 47.8 dollars per cubic metre typical of soil washing and excavation.

Jack bean is the authors’ candidate plant of choice. This Central and South American native grows rapidly and sends down a deep, well-branched root system that releases exudates rich in carbohydrates, organic acids and amino acids. Those compounds feed soil microorganisms, stimulating rhizosphere colonisation including Pseudomonas populations, while the bacteria reciprocate by producing phytohormones such as auxins, cytokinins and gibberellins, solubilising nutrients and dampening contaminant-induced oxidative stress. Jack bean also partners with nitrogen-fixing microbes, improving soil fertility and creating conditions favourable for bioremediation. Related evidence supports the concept: combining hairy vetch with the bacterium Arthrobacter ATR1 removed more atrazine than either partner alone and enriched xenobiotic-degrading bacteria in the rhizosphere, and in glyphosate studies, isolates from contaminated farmland outperformed forest-soil isolates, with mixed genera delivering the highest growth and degradation rates.

Weaving the three components together produces what the authors describe as a rhizosphere functioning as a highly resilient bioreactor. Biochar regulates contaminant dynamics and buffers soil chemistry, Pseudomonas actively mineralises the xenobiotic, and jack bean sustains the whole assembly through root exudates and biomass inputs. The design directly addresses a chronic weakness of single-agent bioremediation, which often fails in the field because one strategy alone cannot both neutralise the toxin and rebuild a functioning soil community. By rapidly reducing the bioavailability of atrazine and its toxic metabolites while sustaining high microbial metabolic activity, the integrated approach lowers ecotoxicological risk and strengthens the agroecosystem’s resilience against future contamination.

The authors are candid about the hurdles. Synthesising biochar with optimised porosity for atrazine adsorption demands strict control of pyrolysis temperature and residence time, and the variability of raw biomass makes standardisation difficult. Jack bean’s performance depends on rainfall and soil fertility, narrowing the biological window in which the system can respond to acute contamination. The biggest bottleneck, however, is bacterial survival: introduced Pseudomonas face fierce competition from native microbiota, predation by protozoans and nematodes, and abiotic stresses such as ultraviolet radiation, temperature swings and drought. Without protective formulations such as encapsulation or biofilms, the degrading population may crash before it establishes. Long-term field trials, the authors caution, remain essential to validate the interactions under diverse environmental conditions.

Even with those caveats, the outlook is striking. Advances in feedstock selection, pyrolysis control and surface modification are producing biochars tailored for specific chemical functionality, and modern multi-omics tools are enabling the selection of stable, efficient microbial consortia for field use. The authors propose that future research expand plant-microorganism synergistic systems, develop bioinoculant consortia that combine complementary or engineered strains, and foster collaboration between academia, regulators and agribusiness to commercialise microbial inoculants at scale. If those steps succeed, the humble combination of charcoal, bacteria and a bean plant could become a standard, sustainable practice for restoring pesticide-contaminated farmland worldwide.

Subject of Research: Integrated biochar, Pseudomonas and phytoremediation strategies for degrading atrazine contamination in agricultural soils

Article Title: Combined application between remediation and bioremediation enhances soil xenobiotics decontamination

Article References: Maligeski, K., Carleial, R., & Baron, D. (2026). Combined application between remediation and bioremediation enhances soil xenobiotics decontamination. Discover Plants, 3(1), Article 425. https://doi.org/10.1007/s44372-026-00898-1

Image Credits: AI Generated

DOI: 10.1007/s44372-026-00898-1

Keywords: atrazine, biochar, bioremediation, phytoremediation, Pseudomonas, Canavalia ensiformis, soil decontamination, herbicide persistence, rhizosphere, xenobiotics, sustainable agriculture, soil microbiology

The scale of the screening was ambitious. The researchers measured 975 sweetener–bacterium pairs, growing each bacterial strain in modified Gifu anaerobic medium under strictly anaerobic conditions while exposing it to 50 micromolar concentrations of each sweetener—a level the team estimated to be within the range relevant to the human colon. Growth was tracked hourly for 24 hours, quantified as the area under the growth curve, and any apparent interaction had to pass stringent criteria: statistical significance after correction for multiple testing, a change in growth of at least 20 percent, and confirmation in an independent experiment across five different concentrations. After this rigorous validation, 30 genuine interactions emerged between 26 sweeteners and 5 bacterial strains, none of which had been reported before. Three-quarters of the tested sweeteners individually affected the growth of at least one strain.

Some bacteria proved especially sensitive. Clostridium symbiosum and Lacrimispora saccharolytica were hit by the largest number of compounds, while the sweetener component isosteviol—a stevia-derived molecule widely used in commercial formulations—emerged as the most potent single agent, inhibiting three bacterial species while paradoxically promoting the growth of Lactobacillus gasseri. But the most striking findings came when the researchers moved beyond individual compounds. Because sweeteners are rarely consumed in isolation—they appear alongside caffeine in soft drinks, vanillin in processed foods and even baby formula, and are co-formulated into pharmaceutical tablets to mask bitterness—the team screened 156 sweetener–xenobiotic combinations against all 25 bacteria, yielding 3,900 potential interactions, plus another 300 combinations involving common tablet drugs such as ibuprofen, acetaminophen, and cetirizine.

Using the Bliss model of independence, a classic pharmacological framework in which two compounds are considered synergistic if their combined effect exceeds the product of their individual effects and antagonistic if it falls short, the team identified 102 significant interactions involving nine bacterial species—68 antagonistic and 34 synergistic. Isosteviol was again central, showing combinatory effects with three of the four co-consumed compounds across five bacterial species. The strongest synergy by far was between isosteviol and duloxetine, which together inhibited Roseburia intestinalis, a butyrate-producing bacterium repeatedly linked to glucose homeostasis and protection against intestinal inflammation, and Parabacteroides merdae, a prevalent commensal associated with a healthy microbiota. On the antagonistic side, vanillin buffered the effect of saccharin against Bifidobacterium adolescentis—two compounds that frequently co-occur in processed foods.

To translate single-species effects into community-level consequences, the researchers assembled a synthetic gut community from all 25 strains and passaged it serially in the presence of the solvent control, isosteviol, duloxetine, or the combination. All compound treatments reduced species diversity, but the isosteviol–duloxetine combination was the most disruptive, significantly depleting R. intestinalis, P. merdae, Segatella copri, Bacteroides uniformis, and Phocaeicola vulgatus. Intriguingly, the picture did not simply mirror the monoculture results. R. intestinalis showed synergy in isolation but not in community, while P. merdae showed the reverse—a pattern the authors describe as emergent, meaning that ecological interactions among community members generated effects that could not be predicted from single-species data. Of the 25 strains, 24 grew worse under the combination in monoculture, yet 7 actually benefited in the community setting, underscoring how metabolic cross-feeding can reshape drug and sweetener responses.

What is the molecular mechanism behind this synergy? Proteomic analysis of R. intestinalis and P. merdae after four hours of exposure revealed that the combination produced protein abundance changes that deviated from what would be expected from purely additive single-compound effects. Eleven proteins in R. intestinalis and 29 in P. merdae responded specifically to co-exposure, with no overlap between the two species. In R. intestinalis, many changes clustered in vitamin B5 biosynthesis and fatty acid metabolism, but supplementing cultures with pantothenate, coenzyme A, and 18 other metabolic additives failed to rescue growth, ruling out this pathway as the primary target. In P. merdae, the response was dominated by cell envelope proteins: twelve upregulated proteins were transporters, efflux pump subunits, or envelope components, while the saccharide uptake system subunits SusC and SusD were downregulated—a clear signature of altered small-molecule transport across the membrane.

A genome-wide transposon mutant screen in P. merdae, using a barcoded library covering roughly 3,000 non-essential genes, reinforced this conclusion. Mutants losing the strongest fitness under co-exposure mapped to genes encoding membrane proteins, including a CorA-family putative magnesium transporter, a FadL-family hydrophobic compound transporter, a domain of the outer membrane assembly factor BamD, and a c-di-AMP phosphodiesterase ortholog implicated in membrane homeostasis in the oral pathogen Porphyromonas gingivalis. The CorA transporter stood out because it showed both strong negative fitness and increased protein abundance under duloxetine exposure—yet adding magnesium to the medium did not rescue growth, suggesting the protein performs an unknown homeostatic role rather than simply importing the ion. Bioaccumulation assays added another layer: R. intestinalis accumulated isosteviol only when duloxetine was present, while P. merdae accumulated it even without the drug, consistent with transport changes driving the synergy.

The metabolic consequences were substantial. Untargeted liquid chromatography–mass spectrometry showed that co-exposure reshaped the secreted metabolome of all three tested species, with 16 of 19 significantly altered peaks annotated as di- and tripeptides—microbial products previously linked to blood pressure regulation, Listeria infection, and intestinal inflammation. Targeted quantification of 46 metabolites revealed that in R. intestinalis, co-exposure raised glutamine secretion by roughly 50 percent (about 65 micromolar) and cut butyric acid by more than 25 percent (about 0.6 millimolar), while isovaleric acid—a metabolite correlated with depression in fecal studies—also increased. In P. merdae, asparagine concentrations shifted by more than 200 micromolar. Because butyrate fuels colonocytes, supports insulin sensitivity, and helps maintain anti-inflammatory immune tone, while glutamine can be either protective or harmful depending on context, these shifts carry real implications for host physiology.

The final experiments connected microbial chemistry back to human cells. When HeLa cells were incubated with supernatants from the 25-member community, supernatants from combination-treated communities were significantly more cytotoxic than controls—even controls where the compounds were added to supernatant only after harvesting, proving the toxicity stemmed from altered bacterial metabolism rather than the compounds themselves. In Caco-2 intestinal epithelial cells, the combination-treated supernatant suppressed secretion of the inflammatory cytokines IL-6 and IL-8 by more than 75 percent while leaving IP-10 unaffected. Because IL-6 and IL-8 coordinate neutrophil recruitment and gut defense, the authors caution that such dampening could reflect either anti-inflammatory effects or an impaired capacity to fight pathogens. The team links the cytokine changes to reduced short-chain fatty acids in the community supernatant, and shows that butyrate plus propionate can itself stimulate IL-8 secretion.

The authors are candid about limitations: the screens used a single concentration of 50 micromolar in a single growth medium, the synthetic community contains only 25 taxa, and real-world exposures are far more variable across individuals. Yet prior work suggests roughly 60 percent of monoculture drug effects are preserved in communities, making these findings a credible starting point. What the study makes unmistakably clear is that sweetener safety cannot be evaluated in isolation. Given that duloxetine alone accounted for more than 18 million prescriptions in the United States in a single year, and that sweeteners, caffeine, and vanillin saturate the modern food supply, the sweetener–xenobiotic–microbiome axis may represent an overlooked dimension of public health—one in which the bacteria in our intestines act as silent arbiters of what we eat, what we medicate with, and how our bodies respond.

Subject of Research: Interactions between low-calorie sweeteners, co-consumed xenobiotics, and human gut bacteria in vitro

Article Title: Common xenobiotics modulate gut microbial responses to low‑calorie sweeteners in vitro

Article References: Common xenobiotics modulate gut microbial responses to low‑calorie sweeteners in vitro. (n.d.). https://doi.org/10.1038/s44320-026-00225-6

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00225-6

Keywords: low-calorie sweeteners, gut microbiota, xenobiotics, duloxetine, isosteviol, Roseburia intestinalis, Parabacteroides merdae, bliss synergy, metabolomics, proteomics, cytokines, microbiome

The empirical foundation for this view was laid by large-scale laboratory screens, most notably a 2018 study in which the team around Lisa Maier and Kiran Patil tested roughly 1,000 marketed drugs against representative strains of human gut bacteria and found that about a quarter inhibited at least one commensal microbe. Subsequent work extended the map beyond pharmaceuticals. Recent screens have shown that industrial and agricultural chemicals also suppress gut bacteria in vitro, and that some per- and polyfluoroalkyl substances, the persistent so-called forever chemicals, are actively bioaccumulated by human gut microbes. Even dietary xenobiotics, transformed by resident bacteria, can restructure microbial communities. The boundary between the pharmacy, the food supply and the chemical environment, the review makes clear, is biologically porous.

What distinguishes non-antibiotic antimicrobials from true antibiotics is not the fact of antibacterial activity but its spectrum and potency. Unlike antibiotics, which are typically active at low concentrations and target a broad range of organisms, non-antibiotic antimicrobials tend to act at higher doses and against a narrower set of microbes. Paradoxically, that narrow set often excludes the Enterobacteriaceae, the family containing many classic pathogens for which new antibiotics are urgently needed, while hitting beneficial commensals harder. This inverted selectivity means that everyday exposure to these compounds can quietly erode the protective, health-associated fraction of the microbiome while leaving opportunistic pathogens relatively unscathed, creating ecological vacancies that resistant or disease-associated organisms can exploit.

The molecular mechanisms underlying these effects are only beginning to be resolved, but several recurring strategies have emerged. Some non-antibiotics share drug targets with classical antibiotics or, more intriguingly, bind bacterial counterparts of the human proteins they were designed to hit. Others mimic essential metabolites, poisoning microbial enzymes through molecular masquerade, or hijack bacterial transport systems to gain entry into cells. Individual examples are illuminating: the artificial sweetener saccharin has been shown to disrupt bacterial cell envelope stability and interfere with DNA replication dynamics; nonsteroidal anti-inflammatory drugs target DNA replication; the antidiabetic drug acarbose impairs gut Bacteroides growth by inhibiting intracellular glucosidases; and the Parkinson’s drug entacapone disrupts gut microbial homeostasis through iron sequestration. Yet for the majority of non-antibiotic antimicrobials, the microbial targets remain unknown, a knowledge gap the authors identify as a central obstacle to rational risk assessment.

Crucially, the antimicrobial activity of these compounds cannot be understood in isolation from the host. Microbiome composition varies enormously between individuals, and a drug that devastates one person’s community may barely perturb another’s. Host conditions further modulate outcomes: intestinal pH, bile salt exposure, nutrient availability, body temperature and the community’s biogeography all alter both drug activity and microbial susceptibility. Proton-pump inhibitors, for example, appear to increase the risk of Clostridioides difficile infection primarily by altering gut pH rather than through direct effects on the microbiome, a reminder that host-conditioned mechanisms can masquerade as microbiome effects. Conversely, some drugs act on the host in ways that reshape the gut environment, as with corticosteroids that impair mucin production, or statins whose microbiome-linked effects on metabolic health are still being mapped.

The clinical consequences of these interactions are now measurable in populations. Population-level metagenomic studies have shown that medications leave distinct, reproducible signatures on the gut microbiome, and that drugs taken years before sampling can still act as hidden confounders in microbiome research. One 2025 study reported that non-antibiotics disrupt colonization resistance against enteropathogens, and a companion analysis identified medication-microbiome interactions that affect gut infection outcomes. At the same time, the microbiome can alter drug efficacy in both directions: gut bacterial tyrosine decarboxylases deplete levodopa in Parkinson’s disease, microbial metabolism of the anti-inflammatory mesalazine diminishes its benefit in inflammatory bowel disease, and microbiome-derived metabolites such as inosine and 3-indole-3-acetic acid modulate responses to cancer immunotherapy and chemotherapy. Drug, microbe and host form a three-body problem, the review argues, that medicine has traditionally treated as a two-body one.

Perhaps the most alarming dimension is the contribution of non-antibiotic antimicrobials to the spread of antibiotic resistance. Laboratory and animal studies have shown that antidepressants, antipsychotics, antiepileptic drugs and artificial sweeteners can all promote the horizontal transfer of antibiotic resistance genes, accelerate plasmid conjugation, induce mutagenesis or select for efflux-based resistance in Escherichia coli. Because these compounds are consumed chronically by billions of people and persist in the environment, they may exert a continuous, diffuse selection pressure that quietly amplifies the resistome in human guts and beyond, independent of any antibiotic prescription. The review frames this as a planetary-scale problem, noting that microbiomes across human, animal and environmental habitats are connected by gene flow, so resistance selected anywhere can eventually matter everywhere.

Dietary chemicals occupy a particularly contested middle ground in this landscape. Emulsifiers such as carboxymethylcellulose have been shown in controlled-feeding studies to damage the human gut microbiota and metabolome, while artificial sweeteners have been reported to induce glucose intolerance in mice and personalized, microbiome-dependent glucose responses in humans, though some trials of saccharin and sucralose in healthy adults have found no detectable microbiome effects at all. Pesticide exposure has been associated with altered gut microbiota and metabolites in observational studies of both the general population and occupationally exposed workers. This inconsistency, the authors suggest, reflects the context-dependence that pervades the entire field: identical exposures can yield different outcomes depending on a person’s baseline microbiome, diet, host physiology and co-exposures to other xenobiotics.

The translational implications are substantial. The authors call for integrated stewardship of all xenobiotics, not just antibiotics, across medicine, agriculture, industry and the environment. Practically, that means incorporating microbiome effects into drug development and safety testing, using new high-throughput anaerobic screening methods and defined microbial community models to identify antimicrobial activity before compounds reach patients, deploying chemical-genetic and proteomic tools to pin down microbial targets, and developing computational models of xenobiotic metabolism that can predict how individual microbiomes will respond to given drugs. For clinicians, the immediate lesson is more modest but no less important: non-antibiotic prescriptions are microbiome interventions, and polypharmacy should be recognized as a combinatorial, dose-dependent perturbation of the gut ecosystem.

What the review ultimately delivers is a reframing. Antimicrobial activity, once considered the defining property of a specialized class of drugs, is revealed to be a generic hazard of the chemical world that modern humans inhabit, arising because human and bacterial biochemistry share enough common machinery that molecules designed for one can wound the other. The benefits of these compounds, in treating psychiatric illness, diabetes, cancer and countless other conditions, are real and immense, and the authors are careful not to argue that non-antibiotic antimicrobials should be abandoned. The task, they conclude, is to move from unwitting to deliberate management: to know which compounds disturb the microbiome, through which mechanisms, in whom, and with what downstream consequences for infection risk, chronic disease and resistance, so that the hidden chemistry between our drugs, our food, our environment and our microbes can finally be conducted with open eyes.

Subject of Research: Antimicrobial effects of non-antibiotic compounds on the human gut microbiome and host health

Article Title: Drug–microbiome–host interactions: antimicrobial effects of non-antibiotic compounds

Article References: de la Cuesta-Zuluaga, J., Patil, K. R., & Maier, L. (2026). Drug–microbiome–host interactions: antimicrobial effects of non-antibiotic compounds. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01258-w

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01258-w

Keywords: gut microbiome, non-antibiotic drugs, antimicrobial resistance, microbiome–drug interactions, artificial sweeteners, pesticides, colonization resistance, pharmacomicrobiomics, xenobiotics, dysbiosis, horizontal gene transfer, drug metabolism

Discover Toxicology was inaugurated in May 2024 as a peer-reviewed, open access platform intended to publish research across all aspects of toxicology and its applications in research, development, and society. Its founding premise, the editors explain, is to give researchers, practitioners, policymakers, and stakeholders a venue to exchange knowledge, share best practices, and collaborate on solutions to pressing toxicological challenges. Like other journals in the Discover series, it welcomes all valid research, including null results, regardless of perceived impact, provided the work meets the standards of rigor and quality associated with Springer Nature. That policy is a deliberate counterweight to publication cultures that reward only headline-grabbing findings, a bias the editors argue has left critical dynamics of toxicological mechanisms in low-resourced countries understudied.

The breadth of the journal’s ambition is reflected in its Editorial Board, whose listed expertise spans toxins and venoms, clinical and preclinical pharmacology and toxicology, bioinformatics and cheminformatics, computational chemistry, ecotoxicity, regulatory toxicology, emerging contaminants, food safety, genetic toxicology, analytical chemistry, risk assessment, mechanisms of toxicity, omics, immunotoxicology, forensic pathology, and occupational exposure assessment. In the editorial, each Section Editor introduces the domain he or she represents, offering an unusually candid view of the technical questions the journal considers most pressing.

Professor Adekunle A. Bakare of the University of Ibadan, Nigeria, anchors the genotoxicology section. His laboratory studies the genotoxicity and mutagenicity of xenobiotics, the foreign chemicals that urbanization and industrialization have made almost impossible to avoid. Using in vitro and in vivo bioassays, his group examines the cytotoxic, genotoxic, and mutagenic effects of municipal solid waste leachates, industrial effluents, pesticides, analgesics, medicinal plant extracts, antiretroviral and antituberculosis drugs, metal and metal oxide nanoparticles, and electronic waste elutriates. The stakes, he argues, are generational: DNA damage from environmental xenobiotics is implicated not only in cancer and birth defects but also in heart disease, cellular aging, immune dysfunction, altered metabolism, neurodegenerative disease, and cataracts, and germline damage may affect future as well as current generations. He invites submissions on genotoxicity testing approaches, predictive toxicology, toxicogenomics, reproductive toxicology, epigenetics, gene expression analysis of DNA toxicity, artificial intelligence applied to DNA damage, and the links between genotoxicity and carcinogenesis.

Ajay Vikram Singh, a senior scientist at the German Federal Institute for Risk Assessment (BfR) in Berlin, represents the computational and nanotoxicology frontier. Working within an institute of more than 750 scientists that advises the German government on food and product safety, chemical risks, contaminants, animal protection, and consumer health, Singh combines advanced computational models, artificial intelligence, and nanoscale characterization to decipher how chemicals, nanomaterials, and biological systems interact. The goal is proactive safety assessment: predicting toxicity before products reach the market and enabling the design of inherently safer, so-called safer-by-design materials. He highlights the integration of multi-omics data with computational approaches, the nanobiophysics of mechanistic toxicology, and the regulatory challenges posed by complex novel materials, and he welcomes manuscripts using in silico methods, AI and machine learning-driven predictive toxicology, high-throughput screening data analysis, and mechanistic studies of engineered nanomaterials.

Edmond Sanganyado, associate professor at the University of Saskatchewan, works at the intersection of analytical chemistry and systems biology, developing tools that link exposure to toxicological effect through advanced omics technologies. He frames three questions that he believes will define the field: how to detect and quantify known and unknown toxicants and their metabolites quickly, cheaply, and reliably in real samples; how complex mixtures of pollutants affect organisms, ecosystems, and humans over a lifetime; and how to identify toxic substances in ways that stand up in court, keep pace with drug trends, and support public health. Big data, artificial intelligence, high-resolution mass spectrometry, and new approach methodologies, or NAMs, are driving all three disciplines, analytical, environmental, and forensic toxicology, toward mixture-based paradigms and toward reducing and replacing animal testing. But he cautions that publication norms emphasizing narrow novelty risk leaving the toxicology of low-resourced countries chronically understudied.

Neuropharmacologist João Paulo Capela of Portugal’s Fernando Pessoa University and the University of Porto brings the journal’s coverage to drugs of abuse and clinical toxicology. His research probes the brain actions of amphetamine-type stimulants and methylphenidate, both as illicit substances and as prescribed treatments for attention deficit hyperactivity disorder and other brain disorders. His central concern is translation: whether work is done in vitro or in animals, the purpose of mechanistic toxicology is to transfer findings to the human situation in order to prevent, mitigate, or treat adverse drug effects. He sees artificial intelligence-based tools as a promising means of elevating that mechanistic understanding, and he argues that new methodologies and models are essential for surveying how drugs and toxicants inflict damage at the cellular and molecular level.

Ecotoxicologist Maranda Esterhuizen, affiliated with the University of Helsinki and Häme University of Applied Sciences in Finland, specializes in pollution impact assessment and ecological restoration through nature-based solutions, with a deliberately transdisciplinary approach bridging environmental science and policy. She describes environmental toxicology as standing at a critical juncture, confronting complex chemical mixtures and climate-induced shifts in pollutant behavior, particularly in rapidly urbanizing regions. Her section invites research using adverse outcome pathways, omics technologies, and predictive modeling to understand toxicity across biological scales, and she singles out studies integrating climate change dynamics, urbanization, and chemical mixture interactions as especially welcome, because they mirror the compounded pressures ecosystems actually face.

Food and computational toxicologist Yu-Syuan Luo of National Taiwan University completes the editorial leadership roster. His focus is on human-relevant, mechanism-informed chemical safety evaluation at a time when data gaps for emerging contaminants, low-dose exposures, and complex mixtures impede timely regulatory decisions. Food toxicology, he notes, is pivotal for assessing ingredients, contaminants, and food-contact materials, especially for endpoints such as endocrine disruption and mixture toxicity. Computational toxicology complements it with scalable predictive tools, including in silico modeling, omics-based profiling, and data-driven hazard identification and prioritization, supporting the global shift away from traditional animal testing and toward more efficient, transparent, forward-looking risk assessment.

Taken together, the editorial sketches a discipline in methodological upheaval: from single-compound testing toward mixtures, from animal models toward new approach methodologies, from reactive hazard characterization toward AI-assisted prediction and safer-by-design chemistry. By welcoming null results and prioritizing rigor over novelty, Discover Toxicology is positioning itself as a home for precisely the unglamorous, reproducible, and globally inclusive work that this transition requires, and the editors close with an open invitation to researchers worldwide to submit work spanning fundamental questions and real-world applications alike.

Subject of Research: An editorial by the section editors of the open access journal Discover Toxicology outlining research priorities across genotoxicology, computational and nanotoxicology, ecotoxicology, neurotoxicology, and food toxicology.

Article Title: Discover Toxicology, the future journal for your toxicology research

Article References: Bakare, A. A., Singh, A. V., Sanganyado, E., Capela, J. P., Esterhuizen, M., Luo, Y.-S., & Guo, Y. (2026). Discover Toxicology, the future journal for your toxicology research. Discover Toxicology, 3(1), Article 12. https://doi.org/10.1007/s44339-026-00053-1

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00053-1

Keywords: Discover Toxicology, toxicology, open access publishing, genotoxicity, xenobiotics, computational toxicology, nanotoxicology, ecotoxicology, new approach methodologies, food toxicology, chemical mixtures, risk assessment

Researchers led by Christopher P. Holstege, MD, director of UVA Health’s Blue Ridge Poison Center, examined reports submitted to U.S. poison centers from 2000 through 2024. When the data were adjusted for population growth, the rate of reported xenobiotic-related liver injury rose from 10.9 cases per million people to 52.9 cases per million. That represents an increase of almost 400 percent. The study does not mean that every liver injury in the country was captured, because poison center records reflect calls made by the public and health professionals rather than a complete national registry. However, poison centers are an important source of real-time toxicological surveillance, allowing scientists to detect changes in exposure patterns before they become visible in slower-moving health statistics.

More than 80 percent of the reported cases required inpatient medical care, suggesting that many of the exposures were clinically serious rather than minor or transient reactions. The liver is particularly vulnerable to toxic substances because it receives blood from the digestive tract and is responsible for chemically modifying, storing and eliminating a vast range of compounds. During this process, enzymes can convert an otherwise harmless substance into a reactive metabolite capable of damaging liver cells. Injury may begin with inflammation or cellular stress and progress to impaired bile flow, widespread hepatocyte death, acute liver failure and, in the most severe cases, the need for transplantation.

Medications accounted for the majority of the injuries recorded in the study, with acetaminophen emerging as the most frequently implicated substance. The drug is widely used to reduce pain and fever and is present in hundreds of prescription and nonprescription products. Under normal conditions, the liver safely processes most acetaminophen through chemical pathways that produce inactive compounds. A smaller fraction is converted into a reactive metabolite known as N-acetyl-p-benzoquinone imine, or NAPQI. The body normally neutralizes NAPQI with the antioxidant glutathione, but excessive doses can deplete glutathione and allow the metabolite to attack liver proteins and cellular structures.

The study found that liver injuries associated with acetaminophen-containing combination prescription products fell sharply—by approximately 60 to 85 percent—after the U.S. Food and Drug Administration limited the amount of acetaminophen permitted in those medicines. The decline suggests that regulatory action reduced the risk created by products that combined acetaminophen with other active ingredients, particularly when patients were unaware that multiple medicines contained the same pain reliever. At the same time, injuries linked to acetaminophen taken by itself increased steadily over the period studied. That pattern indicates that the drug remains a major source of toxic exposure even as one category of combination products has become safer.

Women had higher rates of acetaminophen-associated liver injury than men, while suspected suicide was the most common reason for exposure in both sexes. The data point to the importance of distinguishing accidental medication errors from intentional overdoses, because the medical response, prevention strategies and public health interventions differ substantially. Accidental exposure can occur when patients take several products with overlapping ingredients, misunderstand dosing instructions or use more than recommended while attempting to control severe pain or fever. Intentional ingestion requires rapid emergency assessment as well as mental health support. In either situation, early treatment is critical because symptoms may be mild or absent during the first stage of acetaminophen poisoning.

Alcohol was the second most common contributor to reported liver injuries, although it occurred far less frequently than acetaminophen-related cases. Alcohol-associated injuries were reported more often among men than women, but exposures increased in both groups during the COVID-19 pandemic. Alcohol can injure the liver through several overlapping mechanisms, including the accumulation of toxic metabolic products, oxidative stress, disruption of fat metabolism and activation of inflammatory pathways. Repeated heavy exposure can lead to fatty liver, alcoholic hepatitis and scarring, while a particularly large exposure or combination with other toxic substances may produce acute injury. The pandemic-era increase observed in poison center reports mirrors broader concerns about changes in alcohol consumption and substance use during periods of social disruption.

The researchers also documented rising reports involving stimulants, illicit drugs, herbal and dietary supplements and environmental toxins. These categories were less common than acetaminophen and alcohol, but they reflect a growing challenge for clinicians and poison specialists: the chemical landscape of consumer exposure is constantly changing. Supplements may contain concentrated botanical compounds, undisclosed pharmaceuticals or contaminants, and their formulations can vary between products and batches. Stimulants and street drugs may be mixed with other substances that increase toxicity, while environmental chemicals can affect the liver through metabolic activation or prolonged low-level exposure. Because many emerging products are not subject to the same premarket testing as approved medicines, identifying the exact substance and dose can be difficult during an emergency.

Holstege said the findings underscore the need for consumers to follow clinical advice and pharmaceutical label instructions, while exercising particular caution with unregulated or newly emerging substances. The results also demonstrate how poison centers can function as an early-warning system for public health. Their records can reveal shifts in drug-related harm, identify vulnerable populations and show whether a policy change is associated with a meaningful reduction in poisoning. Still, the study’s observational design cannot prove that every increase resulted from a single cause. Changes in calling behavior, awareness of poison center services, clinical recognition, product availability and patterns of intentional self-harm may all influence the numbers. Even with those limitations, the scale and persistence of the increase point to a widening need for medication safety education, clearer labeling, careful supplement oversight and rapid access to toxicology expertise.

UVA Health’s Blue Ridge Poison Center provides free, confidential guidance around the clock for suspected poison exposures, including medication overdoses and possible liver-toxic substances. The center can be reached in the United States at 1-800-222-1222. People should not wait for symptoms before seeking advice, particularly after a suspected acetaminophen overdose, because serious liver injury can develop while early warning signs remain subtle. The new study, published in Clinical Gastroenterology and Hepatology, was authored by Eleanor Blair Towers, Christopher P. Holstege, Scott Schmalzried and Rita Farah. The researchers reported that they had no financial interest in the work.

Subject of Research: People

Web References: https://makingofmedicine.virginia.edu/

References: Clinical Gastroenterology and Hepatology

Image Credits: UVA Health

Keywords: liver injury, acetaminophen, poisoning, xenobiotics, poison centers, medication safety, alcohol-related liver disease, dietary supplements, toxicology, UVA Health